FDA Approves Journavx- A Game-Changing Non-Opioid Painkiller In Over 20 Years
In a significant advancement for pain management, the U.S. Food and Drug Administration (FDA) has approved Journavx (suzetrigine), a first-in-class non-opioid analgesic designed to treat moderate to severe acute pain in adults. This approval marks the first time in over two decades that a novel non-opioid pain medication has been introduced, offering a promising alternative … Read more